BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY
- None.
- None.
Insights
The filing of a Drug Master File (DMF) for ExCellerate GMP iPSC Expansion Medium by Bio-Techne Corporation represents a significant step in the development of regenerative medicine and stem cell therapy products. This medium is crucial for the expansion and maintenance of induced pluripotent stem cells (iPSCs), which are pivotal in modern therapies for a range of diseases, including genetic disorders and degenerative diseases.
From a research perspective, the availability of a GMP-grade medium that is animal-free reduces the risk of contamination and immunogenic reactions, which is a critical consideration in cell therapy products. The consistency and reproducibility this medium promises are vital for clinical applications, as they ensure that the therapies developed are both safe and effective for patients.
The impact on the business landscape, particularly for companies involved in regenerative medicine, could be substantial. This development may streamline the transition from research to clinical application, potentially accelerating the time-to-market for new therapies. Consequently, this could lead to increased revenue streams for Bio-Techne and its partners, as well as potentially providing a competitive edge within the biotech industry.
The regenerative medicine sector is rapidly evolving and Bio-Techne's introduction of an animal-free GMP medium for iPSCs reflects the industry's move towards more ethical and safe production practices. The DMF filing with the FDA is a proactive measure that not only facilitates regulatory compliance but also demonstrates Bio-Techne's commitment to quality and safety.
For stakeholders, the implications are multifaceted. On one hand, the adoption of such a medium could reduce costs associated with the transition from preclinical to clinical phases, which is often a significant hurdle for biotech firms. On the other hand, it sets a new standard that could pressure competitors to innovate and invest in similar solutions to remain competitive.
Investors may view this development positively, as it indicates Bio-Techne's strategic positioning in a niche but growing market. However, the actual financial impact will depend on the adoption rate of the medium by the industry and the outcome of subsequent therapies developed using it.
The filing of a DMF is a critical regulatory step and can be an indicator of a company's progress towards commercialization of its products. For Bio-Techne, the submission for its ExCellerate GMP iPSC Expansion Medium could lead to an enhanced product portfolio and potentially increased market share in the regenerative medicine space.
Financially, the development of a GMP-grade, animal-free medium may lead to cost savings in production and reduce barriers during the FDA approval process for therapies developed using the medium. This efficiency can translate into a stronger bottom line for Bio-Techne, particularly if the medium becomes an industry standard.
Long-term benefits could include sustained revenue growth and stronger partnerships with pharmaceutical companies investing in regenerative medicine. However, the capital required for research and development, as well as the risks associated with the FDA approval process, should be accounted for when evaluating the company's financial prospects.
ExCellerate GMP iPSC Expansion Medium is optimized to support robust expansion and maintenance of stem cell culture for enhanced consistency and reproducibility throughout the stem cell manufacturing process. The recently released GMP medium complements Bio-Techne's industry leading regenerative medicine therapy workflow solutions, which includes the widest range of GMP cytokines and growth factors available on the market. The ready-to-use media is manufactured without the use of animal components and is available in preclinical and GMP grades to simplify transition from research to clinic.
The DMF submission provides the FDA with detailed information about the facilities and processes used in the manufacturing, processing, packaging, and storing of ExCellerate GMP iPSC Expansion Medium. Regenerative medicine and stem cell therapy developers who integrate the medium into their GMP cell manufacturing workflows can easily reference these important details when filing Investigational New Drug (IND) applications with the FDA.
"Minimizing variability is the keystone to success when developing stem cell-based therapies. Our ExCellerate iPSC expansion media offer consistent, scalable performance, enabling our customers to develop life changing therapies faster," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We are proud to provide our cell therapy customers with reliable workflow solutions and analytics tools for consistent and precise cell manufacturing. This recent DMF submission is yet another example of our commitment to support our customers with the highest-quality reagents and the documentation required for regulatory approval of their novel stem cell-based therapeutics."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-submission-of-fda-drug-master-file-for-excellerate-gmp-ipsc-expansion-medium-supporting-stem-cell-therapy-302019517.html
SOURCE Bio-Techne Corporation
FAQ
What did Bio-Techne Corporation (NASDAQ: TECH) announce?
What is the purpose of ExCellerate GMP iPSC Expansion Medium?
What does the DMF submission provide to the FDA?
What is unique about the ExCellerate GMP iPSC Expansion Medium?
